DFine Announces Completion of STAR™ Tumor Ablation System Phase I Release
6/14/2012 10:45:16 AM
SAN JOSE, Calif.--(BUSINESS WIRE)--DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, today announced an upcoming poster presentation at the World Congress of Interventional Oncology (WCIO), June 14-18 in Chicago. The poster, “Radiofrequency Ablation and Vertebral Augmentation of Bone Metastasis of the Spine: Early Experience of a Novel Minimally-Invasive Technology,” will be presented on Thursday, June 14 at 9:30-10:30 a.m. and 3:45-5:00 p.m. and on Saturday, June 16 at 4:00-5:00 p.m. The poster covers the initial pre-clinical and clinical use of the STAR™ Tumor Ablation System using targeted radiofrequency ablation (t-RFA) for the treatment of metastatic vertebral body tumors.